[
  {
    "ts": null,
    "headline": "Amgen Announces Significant Survival Benefit for Lung Cancer Drug IMDELLTRA in Phase 3 Trial",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 2, Amgen announced new interim results from the global Phase 3 DeLLphi-304 trial for its drug IMDELLTRA (tarlatamab-dlle). The data were presented at the 2025 ASCO Annual Meeting and published in The New England Journal of Medicine. It […]",
    "url": "https://finnhub.io/api/news?id=ade9c6a07583000661c09cc57a6742ec84f2214dc11119de14e60272eb9827bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749980324,
      "headline": "Amgen Announces Significant Survival Benefit for Lung Cancer Drug IMDELLTRA in Phase 3 Trial",
      "id": 135285503,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 2, Amgen announced new interim results from the global Phase 3 DeLLphi-304 trial for its drug IMDELLTRA (tarlatamab-dlle). The data were presented at the 2025 ASCO Annual Meeting and published in The New England Journal of Medicine. It […]",
      "url": "https://finnhub.io/api/news?id=ade9c6a07583000661c09cc57a6742ec84f2214dc11119de14e60272eb9827bc"
    }
  }
]